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Cellular immune responses play a pivotal role 
in the ability of HIV-infected individuals to 
control viral replication (1). The immune sys-
tem, however, ultimately fails to control the 
virus and the majority of HIV-infected pa-
tients develop AIDS. Several mechanisms of 
viral immune evasion have been proposed 
(2–4). Accumulated data suggest that the func-
tional capacity of HIV-specifi  c CD8+ T cells 
is adversely aff   ected by HIV infection. Un-
der chronic antigen stimulation HIV-specifi  c 
CD8+ T cells, which lack CD4+ T cell help, 
express an impaired ability to produce cyto-
kines (termed “exhaustion”) (5). Part of the 
CD8+ T cell profi   le in HIV infection also 
involves an impaired ability to survive and 
proliferate (6) that could further contribute to
the overall impairment in cytokine   production. 
Therefore, therapeutic interventions that en-
hance the survival of these cells could also aug-
ment their proliferative and cytokine functions, 
thereby leading to improved immune control 
of HIV infection.
A variety of manipulations can augment 
HIV-specifi  c CD8+ T cell responses in vitro. 
Treatment with cytokines (i.e., IL-2 and IL-
15) can increase survival and eff  ector function 
of these cells (7, 8). Furthermore, cross-linking 
of costimulatory T cell receptors such as 4-
1BB, CD80, and OX40 has been previously 
described to enhance HIV-specifi  c  CD8+ T 
cell responses either directly (9, 10) or indi-
rectly (11). However, blocking of negative T 
cell regulators off  ers an alternative approach to 
restoring T cell function. Emerging data indi-
cate that the outcome of a T cell response is, at 
least in part, dependent on the interplay be-
tween positive and negative costimulatory 
molecules expressed on T cells and antigen-
presenting cells (12, 13). Recently, restoration 
of exhausted virus-specifi  c CD8+ T cells in a 
mouse model of chronic lymphocytic chorio-
meningitis virus infection was achieved by 
blocking programmed death (PD)-1, but not 
CTLA-4 (14), two negative regulators of T cell 
activation and function (15). PD-1 is the  newest 
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member of the CD28 family, expressed on activated CD4+ 
and CD8+ T cells, B cells, and macrophages (16). Although 
there is some evidence showing delivery of positive signals by 
the ligands of PD-1, programmed death ligand (PD-L)1 and 
PD-L2, (17, 18) the vast majority of the data point to nega-
tive regulation of T cell activation, proliferation, and cyto-
kine production by these ligands (19–21). In support of this 
negative role, in vitro studies using primary human T cells 
have shown that PD-1 ligation can inhibit TCR-mediated 
signaling by reducing phosphorylation of ZAP70, activation 
of PKCθ (22), and activation of Akt (23). PD-1 was   originally 
cloned from cell lines exhibiting high sensitivity to apoptosis 
(24). More recently, induction of apoptosis of   tumor-specifi  c 
CD8+ T cells by PD-L1 was described (25), a process medi-
ated by other receptors in addition to PD-1 (25). Therefore, 
induction of apoptosis could be a key mechanism used by the 
PD-1–PD-L system to aff  ect the outcome of a virus-specifi  c 
T cell response.
Importantly, blockade of PD-1 has been shown to be ef-
fective in enhancing virus-specifi  c CD8+ T cell responses 
Figure 1.  PD-1 is highly expressed on HIV-specifi  c CD8+ T cells. 
(A) Representative histograms depicting PD-1, PD-L1, and PD-L2 expres-
sion in monocytes, mDCs, and pDCs from one subject tested. Cell prepa-
rations from at least three donors were tested. (B) The polychromatic 
fl  ow cytometry gating scheme for identifi  cation of cell populations is 
shown. Histograms depict the PD-1 expression in HIV- and CMV-specifi  c 
CD8+ T cells from the same sample. Memory subsets identifi  ed by CD27 
and CD45RO staining of total CD8+ T cells are presented. (C) Pooled data 
showing the percentage of CD8+ T cells expressing PD-1+ phenotype in 
total CD8+ T cells from healthy donors (n = 7) and HIV+ individuals 
(n = 17), HIV-specifi  c (n = 11), CMV-specifi  c (n = 12), and EBV-specifi  c 
(n = 5) CD8+ T cells from HIV+ individuals, and VV-specifi  c CD8+ T cells 
from vaccinated healthy donors (n = 3). PD-1 expression in memory 
subsets of total CD8+ T cells from HIV+ and healthy donors is also 
shown. Horizontal lines depict mean values. The p values were calculated 
using Student’s t test.JEM VOL. 203, October 2, 2006  2283
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in mice lacking CD4+ T cell help (14), raising the possibil-
ity that, if such negative regulation of CD8+ T cell func-
tion were operative in HIV infection, blocking this pathway 
might enhance HIV-specifi  c CD8+ T cell function. Here, 
we report on the expression of PD-1 on HIV-specifi  c CD8+ 
T cells, and CD8+ T cells specifi  c for other viruses, and the 
consequences of manipulating the PD-1–PD-L system on 
survival, proliferation, and cytokine production by these cells. 
We found that HIV-specifi  c CD8+ T cells express high levels 
of PD-1 that may play a critical role for their survival, and 
that the control of survival is the predominant mechanism 
through which PD-1 aff  ects HIV-specifi  c T cell function.
RESULTS
HIV-specifi  c CD8+ T cells express high levels of PD-1 
independently of their maturational status
PD-1 has two known ligands, PD-L1 and PD-L2 (26). We 
fi  rst investigated the expression of PD-1 and its ligands on 
antigen-presenting cells: monocytes, myeloid dendritic cells 
(mDCs) (27), and plasmacytoid dendritic cells (pDCs) (28–
30). We purifi  ed human CD11c+ mDCs and CD123+ pDCs 
from elutriated monocytes (31, 32). In vitro activation of pu-
rifi  ed monocytes with LPS resulted in up-regulation of PD-
L1, whereas PD-1 and PD-L2 were less aff  ected (Fig. 1 A). 
Cross-linking of toll-like receptor (TLR)7 or 8 (with the 
TLR7/8 ligand Resiquimod) on mDCs substantially stimu-
lated the expression of both PD-L1 and PD-L2 and caused 
a slight induction in PD-1 expression (Fig. 1 A). In marked 
contrast, TLR7/8-mediated activation of pDCs had no eff  ect 
on either PD-1 or its ligands, suggesting that pDCs are not 
involved in regulating CD8+ T cell function via PD-1–PD-L 
interactions (Fig. 1 A). Our data indicate that mDCs and 
monocytes, in addition to presenting antigen and costimula-
tory signals to virus-specifi  c CD8+ T cells, may also serve to 
regulate CD8+ T cell function through the expression of 
PD-1–specifi  c ligands.
We next assessed the expression of PD-1 on naive, mem-
ory, and virus-specifi  c CD8+ T cells using polychromatic 
fl  ow cytometry. The gating scheme for identifi  cation of the 
various CD8+ T cell subsets is shown in Fig. 1 B. Our results 
show that PD-1 expression on naive (CD27+CD45RO−) 
CD8+ T cells is infrequent in both HIV− and HIV+ donors, 
consistent with previous studies (19, 33) (Fig. 1 C). How-
ever, in HIV+ subjects, PD-1 expression was more frequent 
on CD27+CD45RO+ memory CD8+ T cells than on the 
other memory CD8+ subsets (P = 0.02 and 0.0001 versus 
CD27−CD45RO+ and CD27−CD45RO− memory CD8+ 
T cells, respectively). This distinction was not present within 
memory CD8+ T cells from HIV− subjects. We next assessed 
PD-1 expression on virus-specifi  c CD8+ T cells after staining 
with HIV-, CMV-, EBV-, and vaccinia virus (VV)–specifi  c 
tetramers (example shown in Fig. 1 B). We found diff  erent 
levels of PD-1 expression on memory CD8+ T cells accord-
ing to their specifi  city. In general, HIV-specifi  c and EBV-
specifi  c CD8+ T cells were found to express PD-1 more 
frequently than CMV-specifi  c CD8+ T cells, and VV-spe-
cifi  c CD8+ T cells rarely expressed PD-1 (Fig. 1 C). Similar 
patterns of PD-1 expression with respect to virus antigen 
specifi  city were obtained when PD-1 expression was ana-
lyzed by mean fl  uorescence intensity, rather than the fre-
quency of cells that express a given level of PD-1 (unpublished 
data). We did not see a correlation between plasma viral load 
and PD-1 expression on HIV-specifi  c CD8+ T cells in this 
small group of subjects (unpublished data), although in larger 
cohort studies such an association has been clearly demon-
strated (34, 35).
Figure 2.  PD-1 expression is independent of the maturational sta-
tus of HIV- and CMV-specifi  c CD8+ T cells. (A) Representative fl  ow 
cytometry showing the distribution of PD-1+ and PD-1− HIV- and CMV-
specifi  c CD8+ T cells in memory CD8+ T cell subsets. Cells were gated as 
in Fig. 1. The distribution of total CD8+ T cells is also shown. (B) Pooled 
data showing the percentage of CD8+ T cells in memory populations for 
PD-1+ and PD-1− subsets of HIV-specifi  c (n = 8) and CMV-specifi  c (n = 11) 
CD8+ T cells from HIV-infected individuals. The p values were calculated 
using Student’s t test.2284  PD-1 MEDIATES VIRUS-SPECIFIC CD8 T CELL SURVIVAL | Petrovas et al.
Figure 3.  No direct association between PD-1 expression and 
cytokine production by virus-specifi  c CD8+ T cells. (A) Pooled data 
depicting the percentage of antigen-specifi  c CD8+ T cells that produce 
IFN-γ (left), TNF-α (middle), or IL-2 (right) after stimulation with HIV 
Gag peptides, CMV pp65 peptides, or VV. Cells from HIV+ (n = 7), CMV+ 
(n = 10), and healthy individuals immunized with modifi  ed vaccinia 
virus Ankara (n = 25) were tested. (B) PBMCs from an HIV and CMV 
coinfected subject were stimulated with A2-Gag or A2-CMV peptides, 
and epitope-specifi  c CD8+ T cells were gated according to their expres-
sion of tetramer and/or production of cytokine, and the production of JEM VOL. 203, October 2, 2006  2285
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We asked whether PD-1 expression on antigen-specifi  c 
cells is related to their altered maturational status (6, 36). The 
vast majority of HIV-specifi  c CD8+ T cells was found to 
express a CD27+ phenotype, in agreement with previously 
published data (37). There was no diff  erence in the matura-
tional phenotype of the PD-1+ and PD-1− fractions of HIV-
specifi  c  CD8+ T cells (Fig. 2, A and B). CMV-specifi  c 
CD8+ T cells were evenly distributed among the three 
memory phenotypes defi  ned by CD27 and CD45RO; fur-
thermore, PD-1+ and PD-1− CMV-specifi  c CD8+ T cells 
exhibited the same distribution of these three memory phe-
notypes (Fig. 2, A and B). We also found that there was 
no diff  erence in the expression of other homing and matura-
tional markers (CCR7 and CD57) between PD-1+ and 
PD-1− antigen-specifi  c CD8+ T cells (unpublished data). 
Our data therefore indicate that PD-1 expression is indepen-
dent of the maturational state of antigen-specifi  c memory 
CD8+ T cells.
Expression of PD-1 does not directly affect the ability 
of HIV-specifi  c CD8+ T cells to produce cytokines
Knowing that sustained high levels of PD-1 are associated 
with a diminished ability of LCMV-specifi  c CD8+ T cells to 
produce cytokine in chronically infected mice (14), we hy-
pothesize that PD-1 expression on human HIV-specifi  c 
CD8+ T cells would similarly result in impaired cytokine 
production. We fi  rst confi  rmed that the ability of CD8+ T 
cells to produce cytokines in response to antigen stimulation 
was impaired in those T cells known to express high levels 
of PD-1. We measured IFN-γ, TNF-α, and IL-2 produc-
tion by CD8+ T cells after HIV Gag, CMV pp65, and VV 
stimulation, and assessed the proportion of the cells that 
were able to produce any one of the three cytokines. As 
shown in Fig. 3 A, there was no diff  erence in the proportion 
of the HIV Gag–, CMV pp65–, or VV-specifi  c CD8+ T 
cells that were able to produce IFN-γ, but there was lower 
production of TNF-α and IL-2 by CD8+ T cells known to 
express higher levels of PD-1 (HIV > CMV > VV). This 
confi  rmed that PD-1 expression is associated with impaired 
cytokine (TNF-α and IL-2) production by antigen-specifi  c 
CD8+ T cells.
We next asked if the impaired cytokine function resulted 
directly from the expression of PD-1, or whether the two 
phenomena were only indirectly linked. The expression of 
PD-1 in relation to production of cytokines under short (6 h) 
stimulation was assessed in HIV- and CMV-specifi  c CD8+ T 
cells. Cells were stimulated with peptides corresponding to 
HLA-A2–defi  ned optimal HIV and CMV epitopes, and the 
production of IFN-γ, TNF-α, and IL-2 was measured within 
tetramer+ cells according to PD-1 expression. The data dem-
onstrate that IFN-γ and TNF-α are readily produced from 
PD-1+ cells, whereas IL-2 production is rarely produced 
from either PD-1+ or PD-1− CMV- or HIV-specifi  c CD8+ 
T cells (Fig. 3 B). We next gated on the PD-1+ and PD-1− 
subsets of antigen-specifi  c cells (defi  ned by cytokine produc-
tion and/or tetramer staining) and calculated the proportion 
of the cells that were nonfunctional for cytokine production 
after stimulation with a range of peptide concentrations (Fig. 
3 C). For both HIV- and CMV-specifi  c CD8+ T cells at all 
levels of antigen stimulation, there was no diff  erence in the 
production (or lack thereof) of IFN-γ, TNF-α, or IL-2 be-
tween PD-1+ and PD-1− cells. Therefore, PD-1 expression 
does not appear to be directly responsible for the inability of 
some CMV- and HIV-specifi  c CD8+ T cells to produce 
these cytokines.
We  postulated, however, that PD-1 may not be ade-
quately engaged by its ligands during the ex vivo stimula-
tions. We therefore performed 6-h peptide stimulations in 
the presence and absence of anti–PD-1 antibody to directly 
engage the PD-1 pathway during the time of antigen stimu-
lation. Raw data for one subject and compiled data for three 
subjects are shown in the left and right panels, respectively, of 
Fig. 3 D, and show that engagement of PD-1 during antigen 
stimulation had no eff  ect on the ability of the antigen-specifi  c 
T cells to produce IFN-γ, TNF-α, or IL-2. Collectively, 
these data demonstrate that PD-1 does not directly infl  uence 
the capacity of HIV- or CMV-specifi  c CD8+ T cells to pro-
duce cytokines upon stimulation.
PD-1–PD-L1 manipulation alters virus-specifi  c 
CD8+ T cell proliferation and cytokine production 
by regulating their survival
The major eff  ect of PD-1 blockade in mice was on antigen-
specifi  c CD8+ T cell proliferation (14). HIV-specifi  c CD8+ 
T cells are characterized by limited proliferative capacity in 
chronic HIV infection (38, 39), a defect that is linked to the 
depletion of IL-2–secreting HIV-specifi  c  CD4+ and/or 
CD8+ T cells (7, 39, 40). Therefore, we investigated whether 
stimulation through, or interference with, the PD-1–PD-L1 
pathway could aff  ect the proliferation of HIV- and CMV-
specifi  c CD8+ T cells. CFSE-labeled cells were stimulated 
with HIV- or CMV-specifi  c peptide pools in the presence 
or absence of antibodies against either PD-1 or its ligand 
PD-L1. After 6 d, the frequency of CFSElow cells, in either all 
CD8+ or tetramer+ cells, was compared between cultures that 
had received no blocking antibody, an anti–PD-1 antibody 
cytokine in the PD-1+ and PD-1− subsets was assessed. The left panel 
shows the PD-1 staining of CD8+ cells to demonstrate how the gating 
of PD-1+ and PD-1− cells was chosen. (C) Pooled data showing the per-
centage of nonfunctional virus-specifi  c CD8+ T cells from three HIV-
infected individuals off antiretroviral therapy [(tetramer+cytokine−) × 
100/(tetramer+cytokine−) + (tetramer+cytokine+)] at the different 
  peptide concentrations for both PD-1+ and PD-1− compartments are 
shown. (D) Flow cytometry showing the production of IFN-γ, TNF-α, or 
IL-2 from CD8+ T cells after stimulation with Gag or CMV peptides 
for 6 h in the absence or presence of anti–human PD-1 antibody (left). 
Pooled data are shown on the right. Samples from three HIV+ individuals 
were tested.2286  PD-1 MEDIATES VIRUS-SPECIFIC CD8 T CELL SURVIVAL | Petrovas et al.
(that acts as a PD-1 agonist), or an anti–PD-L1   antibody 
(clone MIH1; reference 41). Representative fl  ow cytometry 
plots are shown in the left panel of Fig. 4 A and composite 
data from multiple experiments are shown in the right panel. 
The data show that stimulation of PD-1, in both HIV- and 
CMV-specifi  c CD8+ T cells, resulted in a decrease in prolif-
erative capacity. Alternatively, blocking of the PD-1–PD-L1 
interaction with an anti–PD-L1 antibody resulted in in-
creased proliferation of both HIV- and CMV- specifi  c CD8+ 
T cells. There was variation in the amount of inhibition or 
augmentation of proliferation that was not directly associated 
with the simple level of PD-1 expression, suggesting that 
PD-1 is not the only factor regulating the ability of antigen-
specifi  c T cells to proliferate.
We postulated that the eff  ect of PD-1 on proliferation 
of antigen-specifi  c T cells would aff  ect the number of   cytokine-
producing cells in a multiday assay. Therefore, the ability of 
cells to produce cytokines after antigen stimulation and 6 d 
of culture was examined. PD-1 cross-linking in the pres-
ence of HIV Gag peptide reduced the frequency of CD8+ 
T cells producing IFN-γ and had minimal eff  ect on the 
frequency of cells producing TNF-α (Fig. 4 B). On the 
other hand, anti–PD-L1 treatment resulted in an increased 
frequency of cells capable of producing both cytokines 
(Fig. 4 B). Collectively, these data indicate that any eff  ect 
of PD-1 engagement on cytokine expression in a multiday 
assay is secondary to enhanced proliferation of cytokine-
producing cells.
We next sought to determine if the previously described 
eff  ects of PD-1 on apoptosis were responsible for the ob-
served eff  ects on proliferation. PD-1 expression was con-
sistently associated with higher sensitivity of total CD8+ T 
cells to both spontaneous and CD95/Fas-induced apop-
tosis, estimated by annexin V surface exposure (Fig. 5 A, 
representative data; Fig. 5 B, compiled data). Apoptosis sen-
sitivity was found to be signifi  cantly higher in HIV-specifi  c 
compared with CMV-specifi  c CD8+ T cells, in agreement 
with previously published data (6, 42), and PD-1+ CD8+ 
Figure 4.  PD-1–PD-L1 manipulation alters virus-specifi  c CD8+ 
T cell proliferation and cytokine production. (A) Representative histo-
grams depicting the CFSE profi  le of CD8+ T cells from an HIV+ donor. 
Pooled data showing the fold change of the percentage of CFSE low cells 
under treatment with aPD-L1 or aPD-1 antibody (right). The percentage 
of cells that divided in the absence of antibody treatment was assigned a 
value of 1. The ratio of the percentage in the presence and absence of 
antibody treatment for each response was calculated. The fold change for 
antigen-specifi  c CD8+ (those that diluted CFSE in response to antigen; 
● and ○) and gated antigen-specifi  c tetramer+ CD8+ T cells (□ and ■) 
is shown. The p values were calculated using Wilcoxon’s paired t test. 
(B) Flow cytometry showing the CD8+ T cells secreting IFN-γ and TNF-α after 
stimulation with Gag peptides in the absence or presence of anti–PD-1 or 
anti–PD-L1 antibodies. Cells cultured for 6 d were restimulated with Gag 
peptides for the last 6 h (left). Pooled data showing the percentage of 
CD8+ T cells producing IFN-γ and TNF-α under these conditions (right). 
At least four patients were tested for each treatment.JEM VOL. 203, October 2, 2006  2287
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T cells were always more sensitive to apoptosis than PD-1− 
CD8+ T cells irrespective of antigen specifi  city (Fig. 5 B). 
Of interest, PD-1− HIV-specifi  c CD8+ T cells often were 
more sensitive to apoptosis than PD-1+ CMV-specifi  c 
CD8+ T cells (Fig. 5 B). We therefore asked whether this 
diff  erence could be secondary to the diff  erent maturational 
phenotypes of HIV- and CMV-specifi  c CD8+ T cells. In 
fact we found that PD-1+CD8+ T cells were more suscep-
tible to both spontaneous and CD95/Fas-induced apoptosis 
compared with PD-1−CD8+ T cells in all memory   subsets 
Figure 5.  PD-1 regulates the in vitro survival of virus-specifi  c 
CD8+ T cells. (A) Representative histograms depicting the annexin V posi-
tivity in total, PD-1+ and PD-1− CD8+ T cells from an HIV+ donor under 
spontaneous or CD95/Fas-induced apoptosis. (B) Pooled data showing the 
percentage of annexin V+ cells in PD-1+ and PD-1− subsets of total (n = 8), 
HIV- (n = 6), and CMV-specifi  c (n = 5) CD8+ T cells from HIV+ individuals. 
(C) Annexin V positivity in PD-1+ versus PD-1− CD8+ T cells in memory 
subsets defi  ned by CD27 and CD45RO markers. (D) PBMCs were cultured 
in the absence or presence of plate-bound anti–PD-1, and the percentage 
of annexin V+ cells was determined for CD8+ T cell subsets with different 
levels of PD-1 expression. Flow cytometry showing the different levels 
of spontaneous and anti–PD-1–induced apoptosis according to the level 
of PD-1 expression (high, medium/high, medium/low, and low) in total, 
Gag- and CMV-specifi  c CD8+ T cells from the same HIV+ donor.2288  PD-1 MEDIATES VIRUS-SPECIFIC CD8 T CELL SURVIVAL | Petrovas et al.
tested, but that sensitivity varied between maturational 
phenotypes (CD27−CD45RO+ > CD27−CD45RO− > 
CD27+CD45RO+; Fig. 5 C), suggesting that PD-1 expres-
sion augments apoptosis sensitivity upon the background de-
fi  ned by maturation and activation status.
Another possible explanation for the greater apoptosis 
sensitivity of HIV-specifi  c CD8+ T cells than CMV-spe-
cifi  c CD8+ T cells is the absolute level of PD-1 expression 
on the cells. Although we had defi  ned CD8+ T cells as be-
ing either PD-1 positive or PD-1 negative, it was appar-
ent that PD-1 expression was higher (as measured by mean 
fl  uorescence intensity) on HIV- than CMV-specifi  c CD8+ 
T cells. We therefore asked if the absolute level of PD-1 
expression on CD8+ T cells was the primary determinant 
of apoptosis sensitivity while further determining whether 
PD-1 ligation directly aff  ected survival of CD8+ T cells. To 
do this, we assessed apoptosis in the presence and absence of 
plate-bound anti–PD-1 in samples from six HIV+ donors. 
The results were consistent for all of the donors, and the 
results from one are shown in Fig. 5 D. We found that HIV-
specifi  c CD8+ T cells had higher expression of PD-1 than 
total or CMV-specifi  c CD8+ T cells, but that irrespective 
of antigen specifi  city, the CD8+ T cells with the highest 
expression of PD-1 were the most sensitive to apoptosis and 
were the cells that augmented their apoptosis to the great-
est extent upon PD-1 ligation. In fact, at medium/low and 
low levels of PD-1 expression, there was low spontaneous 
apoptosis that did not increase with PD-1 ligation, whereas 
at high levels of PD-1 expression, PD-1 ligation augmented 
the apoptosis to 80% or greater irrespective of antigen speci-
fi  city. Therefore, the absolute level of PD-1 expression on 
antigen-specifi  c CD8+ T cells is the primary indicator of 
apoptosis sensitivity and the major determinant of sensitiv-
ity to apoptosis upon PD-1 ligation. Collectively, our data 
strongly support that PD-1 is a critical regulator of CD8+ T 
cell survival in HIV infection.
DISCUSSION
The balance between positive and negative signals delivered 
by costimulatory molecules to T cells appears to be critical 
for the ultimate fate of cellular immune responses (13, 43). 
Recent data (10, 11, 14) suggest that manipulation of T cell 
costimulatory pathways may present a novel approach for en-
hancing and restoring virus-specifi  c CD8+ T cell responses, 
especially in the context of a chronic infection like HIV. We 
report here on the role of PD-1, a negative costimulatory re-
ceptor of T cells, as a regulator of virus-specifi  c CD8+ T cells 
in HIV infection. To understand how PD-1 can aff  ect the 
function of CD8+ T cells, it is critical to identify which cells 
provide the ligand(s) for PD-1. Our data indicate that mDCs 
and monocytes may use the PD-1–PD-L system to regulate 
adaptive antiviral immunity. Our fi  ndings in this context are 
very preliminary and much more needs to be investigated. 
For instance, the relative kinetics of costimulatory molecule 
expression on mDCs and monocytes after activation and the 
impact of the “positive” and “negative” signals delivered by 
these molecules to responding T cells remains to be eluci-
dated. In addition, it will be important to determine whether 
there is redundancy between the various costimulatory sig-
nals aff  ecting CD8+ T cells or if they act independently by 
stimulating separate intracellular pathways after initiation of 
virus-specifi  c CD8+ T cell responses.
We found remarkably high expression of PD-1 on HIV-
specifi  c CD8+ T cells. The frequency of PD-1 expression 
on the diff  erent virus-specifi  c CD8+ T cells (HIV = EBV > 
CMV > VV) is consistent with PD-1 regulation according 
to antigen stimulation. Although it is unlikely that the level 
of antigen in chronic EBV infection reaches that which 
  occurs in HIV infection, it has been shown that EBV is 
continuously shed into saliva by induction of the lytic cycle 
as B cells diff  erentiate into plasma cells, thereby chronically 
stimulating lytic cycle antigen-specifi  c CD8+ T cells (44). 
The mechanism by which CD8+ T cells control HIV and 
EBV may diff  er. Therefore, it may not follow that expres-
sion of PD-1 on EBV- and HIV-specifi  c CD8+ T cells 
will similarly impact CD8-mediated control of these two 
diff  erent virus infections. Further experiments are needed 
to clarify the relative role of PD-1 in regulation of EBV-
  specifi  c CD8+ T cell responses and compare it to the regu-
lation of HIV-specifi  c responses. In summary, although we 
cannot conclude that chronic antigen stimulation is the sole 
factor determining PD-1 expression, our data reveal that 
HIV-specifi  c CD8+ T cells, because of their high expres-
sion of PD-1, may be vulnerable to negative signals deliv-
ered by PD-1, potentially leading to functional consequences 
in vivo.
Despite their diff  erential expression of PD-1, no diff  er-
ence in IFN-γ production was found between HIV-, CMV-, 
and EBV-specifi  c CD8+ T cells. On the other hand, PD-1 
expression is associated with signifi   cantly lower ability of 
HIV-specifi  c CD8+ T cells to produce TNF-α and even 
lower production of IL-2. This is in agreement with the fi  nd-
ing that PD-1–PD-L1 blockage has a substantial impact on 
LCMV-specifi  c CD8+ T cells producing both IFN-γ and 
TNF-α, whereas it has only a slight eff  ect on single IFN-γ 
producers. However, we found that PD-1− and PD-1+ anti-
gen-specifi  c CD8+ T cells were equally able to produce cy-
tokines upon antigen stimulation, indicating that PD-1 
expression has no direct eff  ect on cytokine production. This 
was further supported by our fi  nding that ligation of PD-1 
during antigen stimulation had no eff  ect on cytokine produc-
tion by virus-specifi  c CD8+ T cells. Collectively these data 
clearly demonstrate that PD-1 has no direct eff  ect upon the 
immediate ability of antigen-specifi  c CD8+ T cells to pro-
duce IFN-γ, TNF-α, or IL-2.
Manipulation of the PD-1–PD-L system was found to 
alter the proliferation of virus-specifi  c CD8+ T cells. This 
was accompanied by altered percentages of CD8+ T cells 
producing cytokines. The change in proliferation could re-
sult from an altered ability of these cells to either survive or 
divide. Importantly, we found no relationship between PD-1 
expression and the degree of change in proliferative capacity JEM VOL. 203, October 2, 2006  2289
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after manipulation of the PD-1–PD-L1 axis. In fact, in some 
instances where the expression of PD-1 was very high on 
HIV-specifi  c CD8+ T cells, only minor eff  ects of PD-1 liga-
tion on proliferation were observed. Therefore, although 
PD-1 has a demonstrable eff  ect on the ability of virus-  specifi  c 
(CMV and HIV) CD8+ T cells to proliferate, it is not the 
sole factor regulating this function. This is not surprising as 
other factors (i.e., TCR activation threshold, relative expres-
sion of other costimulatory molecules, or levels of adaptor 
proteins mediating the intracellular signaling delivered by 
PD-1) could also contribute to the ability of PD-1 ligation to 
aff  ect proliferative capacity.
At least two interventions have now proven successful in 
vitro in restoring the proliferation of HIV-specifi  c CD8+ T 
cells: the addition of IL-2 (or CD4+ T cells producing IL-2) 
and the manipulation of costimulatory pathways such as PD-1. 
This raises the question of whether these two diff  erent ma-
nipulations aff  ect proliferation through overlapping intracel-
lular mechanisms. In addition, whether they can act in a 
synergistic mode remains to be elucidated. Since IL-2 cannot 
overcome the proliferative defect in CD57+CD8+ T cells 
(45), it is of particular interest to examine whether manipula-
tion of PD-1–induced pathways could specifi  cally  restore 
their proliferative capacity.
Our data indicate that the primary mechanism by which 
PD-1 aff  ects CD8+ T cell function is by regulating the ability 
of these cells to survive. This is in agreement with the origi-
nally described role of PD-1 as an apoptotic factor (24) and 
the reduced survival that characterizes virus-specifi  c CD8+ T 
cells under conditions of chronic antigen stimulation (46, 
47). We can speculate on how PD-1 expression could aff  ect 
HIV-specifi  c CD8+ T cell survival. It is possible that stimula-
tion through PD-1 can direct cells into a cell cycle resting 
state, as has been described for the PD-1–PD-L2 interaction 
(21). We found that lack of PD-1 expression is associated 
with similar levels of spontaneous and CD95/Fas-induced 
apoptosis, whereas CD95/Fas-induced apoptosis is greatly 
augmented in CD8+ T cells that express PD-1, indicating 
that there may be cross-talk between the signals induced by 
these two receptors. Previously published data have shown 
that the Fas–FasL interaction impacts PD-L1–induced apop-
tosis of activated T cells (25). Although no direct link be-
tween PD-1 and CD95/Fas was described in that work (25), 
the possibility that PD-1 could prime (especially under con-
ditions of chronic stimulation) CD8+ T cells to undergo 
CD95/Fas-induced apoptosis cannot be excluded. There-
fore, clarifi  cation of the intracellular mechanism(s) governing 
the proapoptotic function of PD-1 is of particular interest. 
Furthermore, the role of such a function on CD4+ T cell 
survival in HIV infection would signifi  cantly add to our un-
derstanding of HIV pathogenesis.
A clear conclusion from our results is that the absolute 
level of PD-1 expression is a major determinant of spontane-
ous apoptosis and sensitivity to PD-1 ligation. We conclude 
this despite our observation that PD-1− HIV-specifi  c CD8+ 
T cells are often more susceptible to apoptosis than PD-1+ 
CMV-specifi  c CD8+ T cells (Fig. 5 B). Although it is known 
that sensitivity to apoptosis is also aff  ected by other factors—
specifi  cally the level of T cell activation (defi  ned by CD38 
expression; unpublished data) and maturational state, which 
we have shown is independent of PD-1 expression (Fig. 2, 
A and B and Fig. 5 C)—our data indicate that PD-1 is a pri-
mary determinant of apoptosis sensitivity over and above these 
other factors. We conclude this because, within any popula-
tion of CD8+ T cells (defi  ned by activation, maturation, or 
antigen specifi  city), the PD-1+ population is more sensitive 
to apoptosis than the PD-1− population. In addition, al-
though we have described PD-1 expression as either positive 
or negative in most of our data, expression really represents a 
continuum, with high expression being associated with 
greater impact upon PD-1–regulated functions (i.e., apopto-
sis; Fig. 5 D). When CD8+ T cells of diff  erent antigen speci-
fi  cities, but similar levels of PD-1 expression, are analyzed, 
they exhibit similar levels of spontaneous apoptosis and sensi-
tivity to PD-1 ligation. In addition, cells with moderate to 
low expression of PD-1 have low levels of spontaneous apop-
tosis and are not aff  ected by PD-1 ligation. What this means 
is that within any population of antigen-specifi  c CD8+ T 
cells, it is the absolute level of PD-1 that primarily dictates 
the rate of spontaneous apoptosis and sensitivity to PD-1 li-
gation. Therefore, what is unique about HIV-specifi  c CD8+ 
T cells is their high level of PD-1 expression leading to a 
profound (but potentially reversible) survival defect. Al-
though the proliferative capacity of a CD8+ T cell is deter-
mined by more than just an ability to resist apoptosis, it is not 
diffi   cult to visualize how the level of PD-1 and associated 
sensitivity to apoptosis would impact on the ability of a cell 
to proliferate.
Overall, our data demonstrate that PD-1 is preferentially 
expressed on CD8+ T cells specifi  c for chronic viruses, and 
that PD-1 interaction with its ligands can regulate the ability 
of these virus-specifi  c CD8+ T cells to survive and  proliferate. 
Therefore, manipulation of this axis may lead to at least 
  partial restoration of antigen-specifi  c cell numbers and func-
tion in chronic viral infections such as HIV. It is important 
to remember that our data do not support the ability of 
PD-1 manipulation to restore all of the T cell functions that 
defi  ne functional “exhaustion.” For instance, we have no 
evidence that PD-1 blockade will restore absent cytokine 
functions, and may only aff  ect CD8+ T cell proliferation to 
the degree possible in the context of other as yet undeter-
mined defects in HIV-specifi  c CD8+ T cells. Therefore, 
  although our data identify PD-1 as a potential therapeutic 
target for restoring functional capacity of HIV-specifi  c CD8+ 
T cell responses, it may not be capable of fully restoring 
function. In addition, it should be appreciated that the PD-
1–PD-L1 axis likely evolved to attenuate potentially harmful 
CD8+ T cell responses to both self-antigens and chronic 
pathogens. Given that many non–HIV-specifi  c  CD8+ T 
cells express PD-1 (Fig. 1 C), it is likely that interventions to 
release all CD8+ T cells from PD-1–mediated suppression 
will have untoward eff  ects.2290  PD-1 MEDIATES VIRUS-SPECIFIC CD8 T CELL SURVIVAL | Petrovas et al.
MATERIALS AND METHODS
Patients. PBMCs were obtained from HIV+ and HIV− volunteers and 
cryopreserved until use. None of the HIV-infected subjects in this study 
were on antiretroviral therapy, and they had a range of viral loads from 
<50 to 439,000 per ml. Signed informed consent approved by the rele-
vant  Institutional Review Board was obtained. Samples from VV-naive 
  individuals, preimmunized with modifi  ed vaccinia virus Ankara followed by 
  scarifi  cation with Dryvax, were also used. Samples were taken within 3 mo 
of Dryvax administration. Purifi  cation of DC subsets has been previously 
described (32).
Antibodies. The following directly conjugated antibodies were used: 
CD3-Cy7APC, IFN-γ–FITC, TNF-α–Cy7PE, CD14-FITC, CD11c-PE, 
CD11c-APC, PD-1–PE, PD-L1–Cy7PE, PD-L2–APC (all from BD 
  Biosciences) and CD45RO-TexasRedPE (Beckman Coulter). Annexin 
V-Cy5PE and the following antibodies were conjugated in our laboratory: 
IL-2–FITC, IL-2–APC, CD14–Cascade blue, CD19–Cascade blue, CD8-
Qdot 705, and CD27-Cy5PE. The unconjugated mAbs were obtained from 
BD Biosciences. Cascade blue was obtained from Molecular Probes. Cy5 
was obtained from BD Biosciences. Quantum Dots were obtained from the 
Quantum Dot Corporation. The following APC-labeled tetramers were 
prepared as previously described (48): A2-Gag (S  L  Y  N  T  V  A  T  Y  L  ), A2-CMV 
(NLVPVMTV), A2-Vaccinia (KVDDTFYYV), B8-Nef (FLKEKGGL), 
and A2-EBV (GLCTLVAML).
Cell stimulation. PBMCs were thawed and rested overnight at 37°C. 
  Viability by Trypan blue exclusion was typically ≥90%. 2 × 106 PBMCs 
were diluted to 1 ml with medium containing costimulatory antibodies 
(αCD28 and αCD49d) (1 μg/ml) (Becton Dickinson), monensin (0.7 μg/ml; 
BD Biosciences), brefeldin A (10 μg/ml; Sigma-Aldrich), in the absence 
or presence of indicated amounts (μg/μl) of A2-Gag (SLYNTVATL) or 
A2-CMV (NLVPVMTV) epitope peptides and incubated for 6 h. Cells 
were washed and incubated with pretitrated amounts of APC-labeled A2-
gag or A2-Cmv tetramer for 15 min at 37°C. After washing, cells were 
surface stained with PD-1–PE, CD8–Qdot 705, CD14– and CD19–cascade 
blue, and 156 ng/ml violet amine reactive viability dye (vivid; In  Vitrogen). 
Following permeabilization (Cytofi   x/Cytoperm kit; BD Biosciences), 
cells were stained with IFN-γ–FITC or IL-2–FITC, TNF-α–PECy7, and 
CD3-Cy7APC. Alternatively, cells were left untreated or preincubated 
for 30 min at 37°C with an anti–human PD-1 antibody (AF 1086; R&D 
Systems) (20 μg/ml) and subsequently stimulated with peptides (15mers 
overlapping by 11) corresponding to full-length HIV-1 Gag (2 μg/ml each 
peptide, 5 μl/ml; National Institutes of Health AIDS Research and Refer-
ence Reagent Program) or cytomegalovirus antigen (60 μl/ml; Microbix 
Biosystems Inc.) for 6 h. After a washing step, cells were stained with vivid, 
CD14– and CD19–cascade blue, CD8-Qd705, permeabilized, and stained 
intracellularly with CD3-Cy7APC, IFN-γ–FITC, IL-2–APC, and TNF-
α–Cy7PE. For CFSE studies, PBMCs were washed thoroughly and labeled 
with 0.25 μM CFSE (Molecular Probes). Cells were adjusted to 1.5 × 106 
cells/ml and cultured in the presence of peptides (15mers overlapping by 
11) corresponding to full-length HIV-1 Gag (2 μg/ml each peptide, 5 μl/ml; 
National Institutes of Health AIDS Research and Reference Reagent 
  Program) or cytomegalovirus CF antigen (60 μl/ml; Microbix Biosystems 
Inc.). aCD28/aCD49d (1 μg/ml) was used for costimulation. An unstimu-
lated and a positive control (culture with 1 μg/ml immobilized anti-CD3, 
clone UCHT1; R&D Systems) was included in each assay. Antibodies 
against human PD-1 (AF 1086; R&D Systems) (20 μg/ml) and human 
PD-L1 (16–5983; eBioscience) (25 μg/ml) were used for cross-linking of 
PD-1 and PD-L1, respectively. Cells were cultured for 6 d, harvested, and 
stained fi  rst with A2-Gag or A2-CMV tetramer–APC (15 min, 37°C) 
and subsequently with annexin V–Cy5PE, CD3-Cy7APC, and CD8-PE. 
2.5 mM CaCl2 was included in all staining steps. Alternatively, cells were cul-
tured under the same conditions, and on day 6 cells were stained with vivid 
and CD8-Qd705 and intracellularly with CD3-Cy7APC, IFN-γ–FITC, 
IL-2–APC, and TNF-α–Cy7PE.
Apoptosis studies. 1–1.5 × 106 PBMCs were cultured in 24-well plates 
(BD Biosciences) in the absence or presence of plate-bound anti–human 
CD95/Fas (IgM, CH11; Upstate Biotechnology) (5 μg/ml) or anti–human 
PD-1 (AF 1086, R&D Systems) (20 μg/ml) for 12 h at 37°C. Cells were 
harvested, washed, and surface stained with APC-labeled A2-Gag, A2-
CMV, or B8-Nef tetramers, and subsequently with annexin V–Cascade 
blue, CD3-Cy7APC, CD8-Qd705, CD27-CyPE, CD45RO-TRPE, and 
PD-1–PE and green amine reactive viability dye (grivid; InVitrogen). 
2.5 mM CaCl2 was included in all staining steps.
Flow cytometry. Cells were analyzed with a modifi  ed LSRII fl  ow cy-
tometer (BD Immunocytometry Systems). Between 200,000 and 1 mil-
lion events were collected. Electronic compensation was conducted with 
antibody capture beads (BD Biosciences) stained separately with individual 
mAbs used in the test samples. Data analysis was performed using FlowJo 
version 6.0 (TreeStar). Forward scatter area (FSC-A) versus forward scatter 
height (FSC-H) was used to gate out cell aggregates. CD14+ cells, CD19+ 
cells, and dead cells were removed from the analysis to reduce background 
staining. The cells were then gated through a FSC-A versus side scatter 
height (SSC-H) plot to isolate small lymphocytes. Next, CD3+ cells were 
selected and PD-1 expression was measured in gated total CD8+ T cells 
and tetramer+ cells, and in relation to their diff  erentiation level by using the 
CD27-Cy5PE and CD45RO-TexasRedPE memory markers. Tetramer+ 
cells were selected and the percentage of PD1+ and PD1−, IFN-γ, and 
TNF-α–producing cells was determined using gating criteria determined 
using the total CD3+CD8+ population. For CFSE analysis, after initial gat-
ing (FSC-A versus FSC-H), apoptotic (annexin V+) cells were removed 
and small lymphocytes were identifi  ed.  CD3+ cells were selected, and 
the percentage of CFSE low cells was determined in gated total CD8+ T 
cells and tetramer+ cells. For analysis of monocytes and DCs, the follow-
ing combinations of titrated antibodies were used: CD11c-APC/CD14-
FITC/PD-1–PE, CD11c-PE/CD14-FITC/PD-L1–Cy7PE/PD-L2–APC, 
and CD123-Cy5PE/PD-1–PE/PD-L1–Cy7PE/PD-L2–APC. PD-1, PD-
L1, and PD-L2 levels were determined in CD14+CD11c− (monocytes), 
CD14−CD11c+ (mDCs), and high CD123 (pDCs) cells.
Statistical analysis. Statistical analysis was performed using Student’s t test 
and Wilcoxon’s paired t test. P values < 0.05 were considered signifi  cant. 
The GraphPad Prism statistical analysis program was used.
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